Concordance between circulating tumor cells and clinical status during follow-up in anaplastic lymphoma kinase (ALK) non-small-cell lung cancer patients
Autor (es)
Provencio Pulla, Mariano

Entidad
UAM. Departamento de MedicinaEditor
Impact JournalsFecha de edición
2017-07-31Cita
10.18632/oncotarget.19722
Oncotarget 8.35 (2017): 59408-59416
ISSN
1949-2553DOI
10.18632/oncotarget.19722Financiado por
This study was supported by Carlos III Institute of Health, Spanish Ministry of Science and Innovation, and European Regional Development Fund (grant number: PI16/01818 and PIE14/00064), D. Pérez-Callejo is supported by SEOM-Río-Hortega contract, A Romero is supported by Joan Rodés fellowship (grant number: JR14/00017) and M Sánchez-Beato is supported by Miguel Servet contract (CP11/00018 and CPII16/00024)Proyecto
Gobierno de España. PI16/01818; Gobierno de España. PIE14/00064Versión del editor
https://doi.org/10.18632/oncotarget.19722Materias
Liquid biopsy; Non-small-cell lung cancer; Circulating tumor cells; ALK-rearrangement; ALK inhibitors; MedicinaDerechos
© 2017 Provencio et al.Resumen
Background: The identification of anaplastic lymphoma kinase (ALK) rearrangements is found in approximately 5% of non-small-cell lung cancers (NSCLCs). However, the development of liquid biopsies as a diagnostic tool is less developed in these cases. This study investigates the use of CTCs during treatment, together with an extended follow-up to correlate with clinical evolution.
Patients and Methods: A total of 13 patients out of a cohort of 212 patients with lung adenocarcinoma, presented ALK rearrangements (6%) confirmed by tumor biopsy. A total of 60 serial blood samples were collected from these patients who were prospectively enrolled in the study.
Results: All patients had a positive CTC count at baseline (mean = 3). The median follow-up was 9 months (range 1-17 months). Three patients underwent surgery and their CTC counts decreased after the procedure but still remained detectable. After radiotherapy, 3 cases showed an average decrease of 5 CTCs. A total of 6 patients were treated with ALK inhibitors and a partial response was observed in 3 of them, who also presented decreased CTC counts. The other 3 patients presented primary resistance, and their CTC counts were higher than those obtained prior to progression.
Conclusion: We believe that the use of CTCs for dynamic monitoring of NSCLC with ALK rearrangement and to detect disease persistence or recurrence may be a reliable technique. CTC counts may also have potential use to monitor the efficacy of ALK inhibitors, facilitating detection of resistance to treatment
Lista de ficheros
Google Scholar:Provencio Pulla, Mariano
-
Pérez-Callejo, David
-
Torrente, María
-
Martín, Paloma
-
Calvo de Juan, Virginia
-
Gutiérrez, Lourdes
-
Franco, Fernando
-
Coronado, María José
-
Cruz-Bermúdez, Juan Luis
-
Martín Ruiz-Valdepeñas, Asunción
-
Cruz-Bermúdez, Alberto
-
Sánchez-Beato, Margarita
-
Romero, Atocha
-
García-Grande, Aránzazu
Lista de colecciones del ítem
Registros relacionados
Mostrando ítems relacionados por título, autor, creador y materia.
-
Dynamic circulating tumor DNA quantificaton for the individualization of non-small-cell lung cancer patients treatment
Provencio Pulla, Mariano; Torrente, María; Calvo de Juan, Virginia
; Gutiérrez, Lourdes; Pérez-Callejo, David; Pérez-Barrios, Clara; Barquín, Miguel; Royuela Vicente, Ana; Rodríguez-Alfonso, Begoña; Sotelo, Miguel; Cruz-Bermúdez, Juan Luis; Mendez, Miriam; Cruz-Bermúdez, Alberto; Romero, Atocha
2017-08-07 -
Cisplatin resistance involves a metabolic reprogramming through ROS and PGC-1α in NSCLC which can be overcome by OXPHOS inhibition
Cruz-Bermúdez, Alberto; Laza-Briviesca, Raquel; Vicente-Blanco, Ramiro J.; García-Grande, Aránzazu; Coronado, Maria José; Laine-Menéndez, Sara; Palacios-Zambrano, Sara; Moreno-Villa, M. Rocío; Martín Ruiz-Valdepeñas, Asunción; Lendinez, Cristina; Romero, Atocha; Franco, Fernando; Calvo de Juan, Virginia; Alfaro, Cristina; Martín Acosta, Paloma; Salas, Clara; Garcia, José Miguel; Provencio Pulla, Mariano
2019-05-14 -
Cancer-associated fibroblasts modify lung cancer metabolism involving ROS and TGF-β signaling
Cruz-Bermúdez, Alberto; Laza-Briviesca, Raquel; Vicente-Blanco, Ramiro J.; García-Grande, Aránzazu; Coronado, Maria José; Laine-Menéndez, Sara; Alfaro, Cristina; Sánchez, Juan Cristóbal; Franco, Fernando; Calvo de Juan, Virginia; Romero, Atocha; Martín-Acosta, Paloma; Salas, Clara; García, José Miguel; Provencio Pulla, Mariano
2018-11-01